

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Dexin Services Group Limited

德信服务集团有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2215)

ANNOUNCEMENT MADE PURSUANT TO RULE 13.51B(2) OF THE LISTING RULES

This announcement is made by Dexin Services Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51B(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to an update of information of Mr. Hu Yiping (“**Mr. Hu**”), an executive director of the Company and chairman of the board of directors (the “**Board**”) of the Company; and Dr. Wong Wing Kuen, Albert (“**Dr. Wong**”), an independent non-executive director of the Company.

The Board noticed that Dexin China Holdings Company Limited (“**Dexin China**”), a connected party of the Group, was ordered to be wound up by the High Court of The Hong Kong Special Administrative Region on 11 June 2024 and the Official Receiver was appointed as the provisional liquidator of Dexin China. Mr. Hu has been an executive director and chairman of the board of directors of Dexin China from 14 August 2018 to 11 June 2024 immediately before the winding up order was granted against Dexin China. Dr. Wong has been an independent non-executive director of Dexin China from 11 January 2019 up to 11 June 2024 immediately before the winding up order was granted against Dexin China.

Dexin China is a company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Main Board of the Stock Exchange (stock code: 2019) and have been suspended from 11 June 2024 and up to the date of this announcement. For further information regarding the winding up of Dexin China, please refer to the respective announcements of Dexin China dated 21 March 2024, 5 June 2024 and 12 June 2024 published on the website of the Stock Exchange. Mr. Hu and Dr. Wong has confirmed that save as disclosed in this announcement, there are no other matters which

are required to be disclose pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, and each of Mr. Hu and Dr. Wong is not aware of any other matters that need to be brought to the attention of the Company and its shareholders.

The Board is undergoing evaluation and seeking professional advice on the impact of the order made against Dexin China, but is of the view that the matter would not affect Mr. Hu's ability to discharge his duties as an executive director of the Company, chairman of the Board, and chairman of the nomination committee of the Company, and also would not affect Dr. Wong's ability to discharge his duties as an independent non-executive director, the chairman of each of the audit committee and remuneration committee of the Company, and a member of the nomination committee of the Company.

By order of the Board
Dexin Services Group Limited
Hu Yiping
Chairman

Hangzhou, the PRC, 14 June 2024

As of the date of this announcement, the Board comprises Mr. Hu Yiping, Mr. Tang Junjie and Ms. Zheng Peng as executive Directors; and Dr. Wong Wing Kuen Albert, Mr. Rui Meng and Mr. Yang Xi as independent non-executive Directors.